Cancer News and Research

Latest Cancer News and Research

Researchers discover protein that stimulates production of beta-amyloid

Researchers at the Fisher Center for Alzheimer's Disease Research laboratory today published "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Drs. Gen He (lead author) and Paul Greengard have discovered a protein that stimulates the production of beta-amyloid, and therefore represents a major new advance in Alzheimer's disease research.

2 Sep 2010

Purdue University researchers develop new type of pump for drug-delivery patches

Purdue University researchers have developed a new type of pump for drug-delivery patches that might use arrays of "microneedles" to deliver a wider range of medications than now possible with conventional patches.

2 Sep 2010

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

Chemotherapy is the best broad defense against cancer recurrence after surgical resection. However, it is difficult to predict which patients will benefit from which regimen of anticancer drugs, if at all. Building on existing knowledge, a study published in the September edition of the Journal of Thoracic Oncology, analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay.

2 Sep 2010

International consortium publishes third-generation map of human genetic variation

An international consortium today published a third-generation map of human genetic variation, called the HapMap, which includes data from an additional seven global populations, increasing the total number to 11 populations. The improved resolution will help researchers interpret current genome studies aimed at finding common and rarer genetic variants associated with complex diseases.

2 Sep 2010

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

Sigma Life Science, the innovative biological products and research services business of Sigma-Aldrich Corporation, today announced the global release of a pioneering range of engineered mammalian cell lines.

2 Sep 2010

Researchers clear hurdle on path toward gene-therapy treatment for disease

One of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques.

2 Sep 2010

Breast cancer classification algorithm to identify 20 gene signature developed using Microsoft Excel

Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

BSD Medical's MicroThermX Microwave Ablation System receives IEC 60601-1 certification

BSD Medical Corporation today reported that the Company has received certification that the MicroThermX Microwave Ablation System (MTX-180) meets all requirements for safety and performance needed for compliance with the IEC 60601-1, safety standard, "Medical Electrical Equipment Part 1: General Requirements for Safety."

2 Sep 2010

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cancer Research UK's Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

2 Sep 2010

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment.

2 Sep 2010

More patients research their own diseases, seek to manage chronic conditions

News outlets report on how the delivery of health care is being changed by empowered patients.

2 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

2 Sep 2010

Study: Preemptive surgery may help prevent cancer for some women

A study published in the Journal of the American Medical Association suggests that women with a gene mutation linked to breast and ovarian cancer face lower risks of developing such cancer after receiving mastectomies or having their ovaries removed, The Wall Street Journal reports.

2 Sep 2010

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).

2 Sep 2010

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer announces that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint.

2 Sep 2010

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Asuragen, Inc., a leader in molecular diagnostics and nucleic acid-based pharmacogenomics services, announced today that it has launched KRAS and BRAF mutational testing services in its CAP-accredited CLIA laboratory.

2 Sep 2010

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 million in a Series D private equity financing.

2 Sep 2010

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate (ADC) that is being developed for the treatment of metastatic renal cancer. An ADC uses the specific binding properties of an antibody to target a toxin in tumor cells, resulting in selective tumor cell killing.

2 Sep 2010

Cancer News and Research

Latest Cancer News and Research

Researchers discover protein that stimulates production of beta-amyloid

Purdue University researchers develop new type of pump for drug-delivery patches

In vitro HDRA improves survival, prognosis of patients with NSCLC: Study

International consortium publishes third-generation map of human genetic variation

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

Researchers clear hurdle on path toward gene-therapy treatment for disease

Breast cancer classification algorithm to identify 20 gene signature developed using Microsoft Excel

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

BSD Medical's MicroThermX Microwave Ablation System receives IEC 60601-1 certification

First Phase I/II clinical trial to test MK-0752 in patients with advanced pancreatic cancer

Cannabis Science issues statement on marijuana study for post-surgery neuropathic pain

More patients research their own diseases, seek to manage chronic conditions

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

TGen researchers use RNAi-based screening to study Ewing's sarcoma

Study: Preemptive surgery may help prevent cancer for some women

Cellerant Therapeutics signs contract with BARDA to develop CLT-008 therapy for ARS

ThromboGenics second microplasmin Phase III trial for non-surgical treatment of VMA meets primary endpoint

Asuragen launches KRAS, BRAF mutational testing in CLIA laboratory

Celator Pharmaceuticals raises $20 million in Series D private equity financing

Agensys commences AGS-16M8F ADC Phase I clinical trial for renal cancer

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Cancer News and Research

Latest Cancer News and Research

Industry Focus: Cell & Gene Therapy eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in